F. Gerard "Gerry" Moeller, MD, is Director of the C. Kenneth and Dianne Wright Center for Clinical and Translational Research, and Associate Vice President for Clinical Research at Virginia Commonwealth University. He is also Director of the Institute for Drug and Alcohol Studies and Division Chair for Addiction Psychiatry. Awarded the C. Kenneth and Dianne Wright Distinguished Chair in Addiction Science, his research focuses on translational research on addictions, with a goal of developing novel treatments that reduce drug use and overdose. He is board certified in Psychiatry and Addiction Medicine.Mishka Terplan, MD, MPH, is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, and advocacy interests lie along the intersections of reproductive and behavioral health. He is Associate Medical Director at Friends Research Institute and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmlineclinician for the National Clinical Consultation Center. He is also the Addiction Medicine Specialist for Virginia Medicaid and a consultant for the National Center on Substance Abuse and Child Welfare. Dr. Terplan has active has published over 100 peer-reviewed articles with emphasis on health disparities, stigma, and access to treatment.

• Chapter 1: Epidemiology of Substance Use Disorders: Opioid Use Disorder EpidemicChapter 2: Epidemiology of Cannabis Use Disorder: Neural Substrates & TreatmentChapter 3: Preclinical Models of Substance Use Disorder: Abuse Liability Assessment and Candidate Pharmacotherapy EvaluationChapter 4: Impulsivity and Drug-Seeking Behavior in Substance Misuse: A Preclinical PerspectiveChapter 5: Impulsivity and Cue Reactivity in Substance Misuse: Clinical StudiesChapter 6: Stress and Substance MisuseChapter 7: Overview: Barriers and Advantages of Utilization of FDA Approved Medications for Substance Use DisorderChapter 8: Methadone for Opioid Use DisorderChapter 9: Use of Buprenorphine for the Treatment of Opioid Use DisorderChapter 10: Antagonist Treatment for Opioid Use Disorder: Development of Antagonist Treatment. Antagonists vs. Agonist Treatments Pros and ConsChapter 11: Pharmacotherapy for Opioid Use Disorders in Special PopulationsChapter 12: Pharmacology of Alcohol Use DisorderChapter 13: Pharmacotherapy for Smoking Cessation: Overview of Medications Including Over-the-Counter Nicotine Replacement Therapy, Bupropion and VareniclineChapter 14: What is "Evidence Based" Treatment?Chapter 15: Evidence Based Behavioral Therapies for Substance Use DisorderChapter 16: Evidence Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorder: Overview and History of Clinical TrialsChapter 17: Evidence Based Pharmacotherapy for Alcohol Use DisorderChapter 18: Turn the Next Page: Envisioning the Future of Addiction Therapeutics

F. Gerard "Gerry" Moeller, MD, is Director of the C. Kenneth and Dianne Wright Center for Clinical and Translational Research, and Associate Vice President for Clinical Research at Virginia Commonwealth University. He is also Director of the Institute for Drug and Alcohol Studies and Division Chair for Addiction Psychiatry. Awarded the C. Kenneth and Dianne Wright Distinguished Chair in Addiction Science, his research focuses on translational research on addictions, with a goal of developing novel treatments that reduce drug use and overdose. He is board certified in Psychiatry and Addiction Medicine.Mishka Terplan, MD, MPH, is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, and advocacy interests lie along the intersections of reproductive and behavioral health. He is Associate Medical Director at Friends Research Institute and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmlineclinician for the National Clinical Consultation Center. He is also the Addiction Medicine Specialist for Virginia Medicaid and a consultant for the National Center on Substance Abuse and Child Welfare. Dr. Terplan has active has published over 100 peer-reviewed articles with emphasis on health disparities, stigma, and access to treatment.

• Chapter 1: Epidemiology of Substance Use Disorders: Opioid Use Disorder EpidemicChapter 2: Epidemiology of Cannabis Use Disorder: Neural Substrates & TreatmentChapter 3: Preclinical Models of Substance Use Disorder: Abuse Liability Assessment and Candidate Pharmacotherapy EvaluationChapter 4: Impulsivity and Drug-Seeking Behavior in Substance Misuse: A Preclinical PerspectiveChapter 5: Impulsivity and Cue Reactivity in Substance Misuse: Clinical StudiesChapter 6: Stress and Substance MisuseChapter 7: Overview: Barriers and Advantages of Utilization of FDA Approved Medications for Substance Use DisorderChapter 8: Methadone for Opioid Use DisorderChapter 9: Use of Buprenorphine for the Treatment of Opioid Use DisorderChapter 10: Antagonist Treatment for Opioid Use Disorder: Development of Antagonist Treatment. Antagonists vs. Agonist Treatments Pros and ConsChapter 11: Pharmacotherapy for Opioid Use Disorders in Special PopulationsChapter 12: Pharmacology of Alcohol Use DisorderChapter 13: Pharmacotherapy for Smoking Cessation: Overview of Medications Including Over-the-Counter Nicotine Replacement Therapy, Bupropion and VareniclineChapter 14: What is "Evidence Based" Treatment?Chapter 15: Evidence Based Behavioral Therapies for Substance Use DisorderChapter 16: Evidence Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorder: Overview and History of Clinical TrialsChapter 17: Evidence Based Pharmacotherapy for Alcohol Use DisorderChapter 18: Turn the Next Page: Envisioning the Future of Addiction Therapeutics

F. Gerard "Gerry" Moeller, MD, is Director of the C. Kenneth and Dianne Wright Center for Clinical and Translational Research, and Associate Vice President for Clinical Research at Virginia Commonwealth University. He is also Director of the Institute for Drug and Alcohol Studies and Division Chair for Addiction Psychiatry. Awarded the C. Kenneth and Dianne Wright Distinguished Chair in Addiction Science, his research focuses on translational research on addictions, with a goal of developing novel treatments that reduce drug use and overdose. He is board certified in Psychiatry and Addiction Medicine.Mishka Terplan, MD, MPH, is board certified in both obstetrics and gynecology and in addiction medicine. His primary clinical, research, and advocacy interests lie along the intersections of reproductive and behavioral health. He is Associate Medical Director at Friends Research Institute and adjunct faculty at the University of California, San Francisco where he is a Substance Use Warmlineclinician for the National Clinical Consultation Center. He is also the Addiction Medicine Specialist for Virginia Medicaid and a consultant for the National Center on Substance Abuse and Child Welfare. Dr. Terplan has active has published over 100 peer-reviewed articles with emphasis on health disparities, stigma, and access to treatment.

• Chapter 1: Epidemiology of Substance Use Disorders: Opioid Use Disorder EpidemicChapter 2: Epidemiology of Cannabis Use Disorder: Neural Substrates & TreatmentChapter 3: Preclinical Models of Substance Use Disorder: Abuse Liability Assessment and Candidate Pharmacotherapy EvaluationChapter 4: Impulsivity and Drug-Seeking Behavior in Substance Misuse: A Preclinical PerspectiveChapter 5: Impulsivity and Cue Reactivity in Substance Misuse: Clinical StudiesChapter 6: Stress and Substance MisuseChapter 7: Overview: Barriers and Advantages of Utilization of FDA Approved Medications for Substance Use DisorderChapter 8: Methadone for Opioid Use DisorderChapter 9: Use of Buprenorphine for the Treatment of Opioid Use DisorderChapter 10: Antagonist Treatment for Opioid Use Disorder: Development of Antagonist Treatment. Antagonists vs. Agonist Treatments Pros and ConsChapter 11: Pharmacotherapy for Opioid Use Disorders in Special PopulationsChapter 12: Pharmacology of Alcohol Use DisorderChapter 13: Pharmacotherapy for Smoking Cessation: Overview of Medications Including Over-the-Counter Nicotine Replacement Therapy, Bupropion and VareniclineChapter 14: What is "Evidence Based" Treatment?Chapter 15: Evidence Based Behavioral Therapies for Substance Use DisorderChapter 16: Evidence Based Pharmacotherapy for Cocaine, Amphetamine, and Methamphetamine Use Disorder: Overview and History of Clinical TrialsChapter 17: Evidence Based Pharmacotherapy for Alcohol Use DisorderChapter 18: Turn the Next Page: Envisioning the Future of Addiction Therapeutics